For our scientists who work for years to create new cancer medicines, the start of patient dosing in clinical trials is a critical milestone.
“The folks in the labs, they're passionate about what their inventions are doing,” explains Steve Davidsen, vice president of oncology discovery at AbbVie.
When a new cancer agent is approved for dosing in patients, the oncology discovery team marks the occasion with a special “molecule hanging” ceremony. After building a wire model of the new agent’s molecular structure, the scientists hang the model from the ceiling in their shared workspace.
In this case, the new molecular agent is the result of over a decade of medicinal chemistry research.
“You have to have people that are willing to go the extra mile—and we do,” Davidsen says. “At the end of the day, all of us are here to see these molecules in cancer patients.”